These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 23419043)
1. Chimera of IL-2 linked to light chain of anti-IL-2 mAb mimics IL-2/anti-IL-2 mAb complexes both structurally and functionally. Tomala J; Kovarova J; Kabesova M; Votavova P; Chmelova H; Dvorakova B; Rihova B; Kovar M ACS Chem Biol; 2013 May; 8(5):871-6. PubMed ID: 23419043 [TBL] [Abstract][Full Text] [Related]
2. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy. Tomala J; Chmelova H; Mrkvan T; Rihova B; Kovar M J Immunol; 2009 Oct; 183(8):4904-12. PubMed ID: 19801515 [TBL] [Abstract][Full Text] [Related]
3. Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera. Votavova P; Tomala J; Kovar M Immunol Lett; 2014; 159(1-2):1-10. PubMed ID: 24512738 [TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of IL-2/anti-IL-2 mAb immunocomplexes exerts synergism with that of N-(2-hydroxypropyl)methacrylamide copolymer-bound doxorubicin conjugate due to its low immunosuppressive activity. Tomala J; Chmelova H; Strohalm J; Ulbrich K; Sirova M; Rihova B; Kovar M Int J Cancer; 2011 Oct; 129(8):2002-12. PubMed ID: 21165950 [TBL] [Abstract][Full Text] [Related]
5. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Boyman O; Kovar M; Rubinstein MP; Surh CD; Sprent J Science; 2006 Mar; 311(5769):1924-7. PubMed ID: 16484453 [TBL] [Abstract][Full Text] [Related]
6. CD8+ memory T cells (CD44high, Ly-6C+) are more sensitive than naive cells to (CD44low, Ly-6C-) to TCR/CD8 signaling in response to antigen. Curtsinger JM; Lins DC; Mescher MF J Immunol; 1998 Apr; 160(7):3236-43. PubMed ID: 9531279 [TBL] [Abstract][Full Text] [Related]
7. IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb. Kamimura D; Sawa Y; Sato M; Agung E; Hirano T; Murakami M J Immunol; 2006 Jul; 177(1):306-14. PubMed ID: 16785526 [TBL] [Abstract][Full Text] [Related]
8. IL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy? Tomala J; Kovar M Oncoimmunology; 2016 Mar; 5(3):e1102829. PubMed ID: 27141363 [TBL] [Abstract][Full Text] [Related]
9. Development of IFN-gamma-producing CD8+ gamma delta+ T lymphocytes and IL-2-producing CD4+ alpha beta+ T lymphocytes during contact sensitivity. Dieli F; Asherson GL; Sireci G; Dominici R; Sciré E; Salerno A J Immunol; 1997 Mar; 158(6):2567-75. PubMed ID: 9058788 [TBL] [Abstract][Full Text] [Related]
10. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation. Wu Z; Xu Y J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116 [TBL] [Abstract][Full Text] [Related]
11. Human high molecular weight melanoma-associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: enhancement of immunogenicity of anti-idiotypic monoclonal antibody MK2-23 by fusion with interleukin 2. Wang X; Ko EC; Peng L; Gillies SD; Ferrone S Cancer Res; 2005 Aug; 65(15):6976-83. PubMed ID: 16061683 [TBL] [Abstract][Full Text] [Related]
12. Selectively expanding subsets of T cells in mice by injection of interleukin-2/antibody complexes: implications for transplantation tolerance. Boyman O; Krieg C; Letourneau S; Webster K; Surh CD; Sprent J Transplant Proc; 2012 May; 44(4):1032-4. PubMed ID: 22564618 [TBL] [Abstract][Full Text] [Related]
13. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795 [TBL] [Abstract][Full Text] [Related]
14. Reversing interleukin-2 inhibition mediated by anti-double-stranded DNA autoantibody ameliorates glomerulonephritis in MRL-lpr/lpr mice. Song YC; Tang SJ; Lee TP; Hung WC; Lin SC; Tsai CY; Ng WV; Wu MF; Sun KH Arthritis Rheum; 2010 Aug; 62(8):2401-11. PubMed ID: 20506162 [TBL] [Abstract][Full Text] [Related]
15. In vivo accumulation of T cells in response to IL-2/anti-IL-2 mAb complexes is dependent in part on the TNF family ligand 4-1BBL. Lin GH; Stone JC; Surh CD; Watts TH Immunol Cell Biol; 2012 Aug; 90(7):743-7. PubMed ID: 21946662 [TBL] [Abstract][Full Text] [Related]
16. Cytokine therapy with interleukin-2/anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+ regulatory T cells and attenuates development and progression of atherosclerosis. Dinh TN; Kyaw TS; Kanellakis P; To K; Tipping P; Toh BH; Bobik A; Agrotis A Circulation; 2012 Sep; 126(10):1256-66. PubMed ID: 22851544 [TBL] [Abstract][Full Text] [Related]
17. Antibody-mediated signaling through PD-1 costimulates T cells and enhances CD28-dependent proliferation. del Rio ML; Penuelas-Rivas G; Dominguez-Perles R; Ramirez P; Parrilla P; Rodriguez-Barbosa JI Eur J Immunol; 2005 Dec; 35(12):3545-60. PubMed ID: 16285013 [TBL] [Abstract][Full Text] [Related]
19. Neutralization of interleukin-2 retards the growth of mouse renal cancer. Fukuhara H; Matsumoto A; Kitamura T; Takeuchi T BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731 [TBL] [Abstract][Full Text] [Related]
20. Specific epitope-induced conversion of CD8+ memory cells into effector cytotoxic T lymphocytes in vitro: presentation of peptide antigen by CD8+ T cells. Kos FJ; Müllbacher A Eur J Immunol; 1992 Jun; 22(6):1595-601. PubMed ID: 1376266 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]